Phenobarbitone Idaman Adverse Reactions

Blood and the lymphatic system disorders: Megaloblastic anaemia (due to folate deficiency), agranulocytosis, thrombocytopenia.
Musculoskeletal and connective tissue disorders: Dupuytren's contracture, frozen shoulder, arthralgia, osteomalacia, rickets.
There have been reports of decreased bone mineral density, osteopenia, osteoporosis and fractures in patients on long-term therapy with phenobarbitone. The mechanism by which phenobarbitone affects bone metabolism has not been identified.
Reproductive and breast disorders: Peyronie's disease.
Psychiatric disorders: Paradoxical reaction (unusual excitement), hallucinations, restlessness and confusion in the elderly, mental depression, memory and cognitive impairment, drowsiness, lethargy, feeling faint, headache, nightmare or trouble sleeping and unusual irritability.
Nervous system disorders: Hyperactivity, behavioural disturbances in children, ataxia, nystagmus.
Cardiac disorders: Hypotension.
Respiratory disorders: Respiratory depression.
Hepatobiliary disorders: Hepatitis, cholestasis.
Skin and subcutaneous tissue disorders: Allergic skin reactions (maculopapular morbilliform or scarlatiniform rashes), other skin reactions such as exfoliative dermatitis, erythema multiforme.
Severe cutaneous adverse reactions (SCARs): Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported.
General disorders and administration site conditions: Antiepileptic hypersensitivity syndrome (features include fever, rash, lymphadenopathy, lymphocytosis, eosinophilia, haematological abnormalities, hepatic and other organ involvement, including renal and pulmonary systems which may become life-threatening), nausea, vomiting.